Easier Measles Vaccines Coming? Microneedle Patch Could Benefit WV's Rural Communities

Why it matters locally: The development of a microneedle patch for measles vaccination has the potential to significantly impact West Virginia, particularly in its rural and underserved communities. With a population of roughly 1.7 million, West Virginia faces challenges in healthcare access, especially in remote areas where reaching medical facilities can be a barrier. The patch's potential for self-administration or administration by less specialized personnel could dramatically improve vaccination rates, reducing the risk of measles outbreaks. This is especially important given WV's population density and some areas with lower rates for vaccines, making them potentially at risk for more severe spread. Recent outbreaks in other states show how swiftly the issues can spiral if preventative measures lag.

---

Atlanta, GA – A collaborative effort between the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) is focused on creating a microneedle patch designed to deliver measles vaccines. The research team hopes the new technology will offer several advantages over traditional injection methods. The patch utilizes microscopic needles, imperceptible to the naked eye, to administer the vaccine under the skin. This method could potentially eliminate the need for trained medical personnel to administer the shots. The developers hope the patch format will make measles vaccination more accessible in locations with limited resources. While details on the patch's composition and clinical trial timelines remain undisclosed, the project signifies ongoing efforts to improve vaccine delivery systems and combat vaccine-preventable diseases like measles. The project aims to create a more stable, easy-to-administer alternative to traditionally refrigerated and injected vaccines. If successful at scale, this could offer wider access to vaccination which could reduce cases and potential spread of the disease.